Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

value

National Institute for Health and Care Excellence NICE logo

UK market access issues put on hold during election

NICE appraisals and Cancer Drugs Fund appeals will not be undertaken until May

- PMLiVE

US cancer drug prices ‘not rational’

New research from the medical journal JAMA adds to growing pressure over pricing

- PMLiVE

Access – the only thing that matters

Our job, at its very core, is to get our medicines into the hands of patients

- PMLiVE

Nurturing innovation in a tough environment

Much has been achieved in the UK in recent years, but the NHS still has a way to go

- PMLiVE

Prioritise educating GPs over patients, says patient advocate

Jack Whelan says that patients are ‘no different to the man on the street’ with health knowledge 

Seismic shifts: Hepatitis C and payers

How hep C is causing paradigm changes in payer behaviour

- PMLiVE

UCB: Patient centricity should move a business forward

Pharma may become obsolete if it does not include the patient voice, says Lode Dewulf

- PMLiVE

R&D productivity takes off

Approvals of NMEs reach heights last seen in the mid-1990s

Anticipating the future in healthcare

New technologies will be key drivers for change

Evolution of the wearable tech revolution

Stuart Goodman delves into the world of wearables, further analysing what role they play in pharma’s future.

Blue Latitude Health

National Institute for Health and Care Excellence NICE logo

NICE system ‘slowing market access to cancer meds’

Two new reports show that UK access to new treatments and survival rates among lowest in Europe

- PMLiVE

Transforming times at AstraZeneca

Lisa Anson, the company’s UK and Ireland president, on AZ's future direction

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links